# Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation

Study · id `cardio:ct-nct06784466` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06784466](<https://clinicaltrials.gov/study/NCT06784466>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06784466

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 360 participants.

## Technical summary

Registry record NCT06784466. Non-randomized; no masking; primary purpose treatment. Start 2025-09-10 (actual); primary completion 2027-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 360 participants (planned count; ClinicalTrials.gov record NCT06784466, source copy `cardio:ctgov-nct06784466-2026-07-15`, retrieved 2026-10-26)
- Started: 2025-09-10 (actual) (ClinicalTrials.gov record NCT06784466, source copy `cardio:ctgov-nct06784466-2026-07-15`, retrieved 2026-10-26)
- Primary completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06784466, source copy `cardio:ctgov-nct06784466-2026-07-15`, retrieved 2026-10-26)
- Completion: 2027-08 (anticipated) (ClinicalTrials.gov record NCT06784466, source copy `cardio:ctgov-nct06784466-2026-07-15`, retrieved 2026-10-26)
- Countries: United States; Belgium; Croatia; Czechia; Lithuania; Netherlands (ClinicalTrials.gov record NCT06784466, source copy `cardio:ctgov-nct06784466-2026-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06784466-2026-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation
- Acronym: COHERENT-AF
- Condition: Atrial Fibrillation (AF)
- Condition: Persistant Atrial Fibrillation
- Condition: Paroxysmal AF
- Intervention (Device): Argá Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
- Lead sponsor: Arga Medtech SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: b9cd2c32c58bd6b1f872b23b1cbb30f34877157d1ec7422f685d87b2dcbf7403
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
